about
Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance.Bioactive proteins and peptides isolated from Chinese medicines with pharmaceutical potential.Constant size, variable density aerosol particles by ultrasonic spray freeze drying.Does the United States Pharmacopeia throat introduce de-agglomeration of carrier-free powder from inhalers?Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance.Evaluation of the correlation between focal adhesion kinase phosphorylation and cell adhesion force using "DEP" technologyElectrostatics of pharmaceutical inhalation aerosols.Production methods for nanodrug particles using the bottom-up approach.Nanotechnology versus other techniques in improving drug dissolution.Electrostatics in pharmaceutical aerosols for inhalation.Delivery of inhalation drugs to children for asthma and other respiratory diseases.Oleanolic Acid Loaded PEGylated PLA and PLGA Nanoparticles with Enhanced Cytotoxic Activity against Cancer Cells.Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus.Effect of Spacers on the Bipolar Electrostatic Charge Properties of Metered Dose Inhaler Aerosols-A Case Study With Tilade®.Pharmacokinetics and pharmacodynamics of dexmedetomidine.Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids.Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.Electrostatic charge characteristics of jet nebulized aerosols.Can low-dose combination products for inhalation be formulated in single crystalline particles?Does electrostatic charge affect powder aerosolisation?Electrostatic charge characteristics of aerosols produced from metered dose inhalers.Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer.Effect of relative humidity on the electrostatic charge properties of dry powder inhaler aerosols.Erratum to: Effect of Crystallinity on Electrostatic Charging in DryPowder Inhaler Formulations.Measuring Bipolar Charge and Mass Distributions of Powder Aerosols by a Novel Tool (BOLAR).Pharmaceutical aerosol electrostatics: a field with much potential for development.Effect of crystallinity on electrostatic charging in dry powder inhaler formulations.Bipolar electrostatic charge and mass distributions of powder aerosols – Effects of inhaler design and inhaler materialElectrostatics in pharmaceutical solidsAerosol Delivery of Nanoparticles in Uniform Mannitol Carriers Formulated by Ultrasonic Spray Freeze DryingNovel Particle Production Technologies for Inhalation ProductsProteins, Peptides, and Controlled-Release Formulations for InhalationPulmonary drug deliveryThe production of dry powder by the sonocrystallisation for inhalation drug deliveryEnhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix formerFormation of Protein Nano-Matrix Particles with Controlled Surface Architecture for Respiratory Drug DeliveryPulmonary Delivery of Peptides and ProteinsChemInform Abstract: Electrostatics of Pharmaceutical Inhalation AerosolsParticle sizes of talc for pleurodesis available in AustraliaElectrostatics of pharmaceutical inhalation aerosols
P50
Q33809597-E970B7BE-FF7D-4045-A28F-29E190F527C1Q33948546-34887CD5-E76B-4477-BF43-1F956A9610C6Q34155627-5781B590-0FAE-4A2E-84E6-99F5B32297CDQ34156985-5CC4495E-BB88-4DD4-BC6C-3FD422B9D87EQ34186206-B7345B5D-03E4-4145-81FA-DAE793262BCAQ36067973-7EE83D87-0B86-4090-863C-28B241D15823Q37643843-65D291CD-1910-408D-9B5D-735B99FC1B1FQ37860433-CD0FE839-976C-4CB2-8A2E-5B61B43300C8Q38104803-20293DC4-3BBA-4F3C-9D65-E77116812744Q38126939-7B44D523-66D4-410A-96E3-AF17C7052E35Q38165641-2EFE282B-8F47-4C6C-8967-D2C00E84181CQ38886207-FA7F5B6B-3629-4A3A-B932-E74EB81C7F81Q38918762-1963DBAB-E7EB-43C6-B2B1-6E9EC5443F1DQ38941256-EDF15640-1522-48D8-B592-D9F471C058FDQ38946488-8D378BEE-221F-4C4B-98BE-54B1A06B8EA2Q39148199-1C5EA627-85CC-49BD-8A84-64AD4D3CDC55Q40762047-3CF8D55E-807D-4FD1-A27A-6A9DC3899599Q43054912-B0C5C55C-2289-416E-8D30-8EA817A5A355Q43155647-95942FC3-52D1-4D60-BDCE-C799C6608295Q43235086-CD84983E-446C-4EAB-A939-D5016EA560F8Q46782633-6E81185B-4589-46BB-A171-981F24686095Q47829347-915DF75C-7474-4CD9-9238-933186F2546BQ50958960-8649AABA-BB40-4CD3-B8C8-6A06D2B3DA7CQ50965219-1766C50B-77EE-4A8F-989C-6F74EB7C9D14Q51829595-C463C9A8-B320-4FF7-AC19-114B7861B581Q53311111-60A9C5E9-A9F4-4D9A-94E1-7CB6AB52D1F3Q53632495-741201DE-CBD6-4C83-8E66-A8813E02145FQ59291738-9C12852A-A189-434E-8559-A549B73525F2Q59291752-68594FD0-7234-4053-B62F-B14D60D942D0Q59291762-845A9763-7717-42A8-AB96-A3DF08007092Q59291772-444DA0B4-2A4C-4084-B4C9-D19B854FF5E8Q59291774-D7E8A90B-9995-4F9B-937D-C5E9BF6FB189Q59291776-0776703B-63B0-4FD8-A360-07676519CC2BQ59291783-5C3E28B3-3DD9-4E8D-90D4-D628FDC82751Q59291797-F7A97042-DAE0-4A7A-B64C-DA7A151168CDQ59291799-569B2A04-3A98-424F-92D3-8DC8A4385798Q59291811-FEE63D37-F733-4D3C-B3DC-E4B7906F28D8Q59291814-408A2803-F2B8-4316-AB98-C7B94A8E0DF8Q59291819-B3F80F07-19C7-49B2-9DDA-71D6461FD8CFQ59291826-6590EC5D-F720-4B31-989C-A0A077D03783
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Philip Chi Lip Kwok
@ast
Philip Chi Lip Kwok
@en
Philip Chi Lip Kwok
@es
Philip Chi Lip Kwok
@nl
Philip Chi Lip Kwok
@sl
type
label
Philip Chi Lip Kwok
@ast
Philip Chi Lip Kwok
@en
Philip Chi Lip Kwok
@es
Philip Chi Lip Kwok
@nl
Philip Chi Lip Kwok
@sl
prefLabel
Philip Chi Lip Kwok
@ast
Philip Chi Lip Kwok
@en
Philip Chi Lip Kwok
@es
Philip Chi Lip Kwok
@nl
Philip Chi Lip Kwok
@sl
P244
P106
P1153
12646007800
P21
P214
42146936829613782472
P244
n2016185602
P31
P496
0000-0002-5362-0671
P735
P7859
lccn-n2016185602